Treatment-Free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries

Treatment-Free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries

We’re pleased to share that the New England Journal of Medicine has published our “Letter to the Editor” on treatment-free remission for chronic myeloid leukemia in low- and middle-income countries!

It was written in collaboration with Dr. Jerry Radich from the Fred Hutchinson Cancer Research Center and partner physicians from Armenia, the Dominican Republic, El Salvador, Ethiopia, Honduras, India, Kenya, and Paraguay.

Read More

See All News

The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.

Related Articles

  • The Max Foundation Partners with Leading Pharmaceutical Company to Advance Health Equity Through Expanded CML Treatment Access for Patients in 36 Low-Middle-Income Countries

    Availability of Novartis Scemblix® (asciminib) starting in 2023 helps ensure people living with later lines of CML in low-income countries have access to the latest innovation SEATTLE – Dec. 12, 2022 – The Max Foundation (Max), a global nonprofit organization that aims to accelerate health equity by delivering medication, technology, and supportive services to patients globally,….

  • Solidarity Fund Celebrates First Delivery

    Solidarity Fund Celebrates First Delivery

    Earlier this month, The Max Foundation celebrated the delivery of 110 BCR-ABL molecular tests to Mercy Medical Center Cambodia. The delivery was the first of its kind for Max, made possible through our 2018 Diagnostics Solidarity Fund. Two more deliveries – one to Kyrgyzstan and one to Bolivia – are in process now, and we’re hopeful there will be many more to come.

  • The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

    The Max Foundation Renews Partnership to Expand Access to Chronic Lymphocytic Leukemia Treatment

    We have extended our partnership with BeOne Medicines and BeOne Care Foundation to provide access to treatment for chronic lymphocytic leukemia (CLL) in low- and middle-income countries, with the program projected to support approximately 1,000 patients cumulatively by the end of 2028. Read the full press release.